{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T02:40:46Z","timestamp":1761964846777,"version":"3.37.3"},"reference-count":30,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2017,4,25]],"date-time":"2017-04-25T00:00:00Z","timestamp":1493078400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Respirology"],"published-print":{"date-parts":[[2017,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Background and objective<\/jats:title><jats:p>Acute exacerbation of idiopathic pulmonary fibrosis (<jats:styled-content style=\"fixed-case\">AE\u2010IPF<\/jats:styled-content>) is recognized as an important cause of mortality. <jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content> has also been reported in patients with other interstitial lung diseases such as idiopathic non\u2010specific interstitial pneumonia (<jats:styled-content style=\"fixed-case\">NSIP<\/jats:styled-content>) and interstitial pneumonia associated with collagen vascular disease (<jats:styled-content style=\"fixed-case\">CVD<\/jats:styled-content>). Current therapies such as high\u2010dose corticosteroid with immunosuppressive agents have provided little benefit for <jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>. Direct hemoperfusion (<jats:styled-content style=\"fixed-case\">DHP<\/jats:styled-content>) with a polymyxin B\u2010immobilized fibre column (<jats:styled-content style=\"fixed-case\">PMX<\/jats:styled-content>) was originally developed for the treatment of endotoxaemia. Recent clinical reports have suggested beneficial effects of <jats:styled-content style=\"fixed-case\">PMX\u2010DHP<\/jats:styled-content> treatment on patients with <jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>. In this study, we evaluated the effectiveness and safety of <jats:styled-content style=\"fixed-case\">PMX\u2010DHP<\/jats:styled-content> treatment for patients with <jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The clinical records of patients with <jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content> admitted to our intensive care unit between 2006 and 2015 were retrospectively reviewed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 54 patients with <jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content> identified from clinical records, 24 were treated with <jats:styled-content style=\"fixed-case\">PMX\u2010DHP<\/jats:styled-content> and 30 were treated without <jats:styled-content style=\"fixed-case\">PMX\u2010DHP<\/jats:styled-content>. The peripheral white blood cell count was significantly decreased (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) and the <jats:styled-content style=\"fixed-case\">PaO<jats:sub>2<\/jats:sub>\n<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">FiO<jats:sub>2<\/jats:sub>\n<\/jats:styled-content> (P\/F) ratio was significantly improved after <jats:styled-content style=\"fixed-case\">PMX\u2010DHP<\/jats:styled-content> (<jats:italic>P<\/jats:italic>\u2009=\u20090.032). While no significant difference was found in the survival proportion between patients treated with and without <jats:styled-content style=\"fixed-case\">PMX\u2010DHP<\/jats:styled-content>, the prognosis of patients with dermatomyositis was significantly improved with the treatment (<jats:italic>P<\/jats:italic>\u2009=\u20090.045). Among the <jats:styled-content style=\"fixed-case\">PMX\u2010DHP<\/jats:styled-content>\u2010treated patients, those who received the treatment within 3\u2009days of <jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content> onset tended to have a better prognosis (<jats:italic>P<\/jats:italic>\u2009=\u20090.026).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The early induction of <jats:styled-content style=\"fixed-case\">PMX\u2010DHP<\/jats:styled-content> treatment may improve the prognosis of patients with <jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>, especially those with dermatomyositis.<\/jats:p><\/jats:sec>","DOI":"10.1111\/resp.13054","type":"journal-article","created":{"date-parts":[[2017,4,25]],"date-time":"2017-04-25T10:43:16Z","timestamp":1493116996000},"page":"1357-1362","source":"Crossref","is-referenced-by-count":17,"title":["Direct hemoperfusion with polymyxin <scp>B<\/scp>\u2010immobilized fibre treatment for acute exacerbation of interstitial pneumonia"],"prefix":"10.1111","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5569-1051","authenticated-orcid":false,"given":"Haruhiko","family":"Furusawa","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine Tokyo Medical and Dental University  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makiko","family":"Sugiura","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine Tokyo Medical and Dental University  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chieko","family":"Mitaka","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Pain Medicine Juntendo University School of Medicine  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naohiko","family":"Inase","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine Tokyo Medical and Dental University  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,4,25]]},"reference":[{"key":"e_1_2_6_2_1","unstructured":"CollardHR MooreBB FlahertyKR BrownKK KanerRJ KingTEJr LaskyJA LoydJE NothI OlmanMAet al.;Idiopathic Pulmonary Fibrosis Clinical Research Network Investigators. Acute exacerbations of idiopathic pulmonary fibrosis.Am. J. Respir. Crit. Care Med.2007;176:636\u201343."},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.07-0323"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2479"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00159709"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-0968.2003.00005.x"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2012.08.032"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.856"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1744-9987.2007.00415.x"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.49.2213"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.3109\/14397595.2013.852847"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.13-0186"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/jca.10019"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-015-0004-4"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201604-0801CI"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/SHK.0b013e3181a2a978"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1843.2010.01774.x"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.42.565"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.50.4327"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.14-2746"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-016-0253-x"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40560-015-0080-9"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.51.6965"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-015-0004-4"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1159\/000321958"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.53.2687"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jss.2009.11.708"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002680020028"},{"key":"e_1_2_6_29_1","doi-asserted-by":"crossref","unstructured":"Meduri GU Headley S Kohler G Stentz F Tolley E Umberger R Leeper K. Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS. Plasma IL\u20101 beta and IL\u20106 levels are consistent and efficient predictors of outcome over time. Chest1995;107:1062\u201373.","DOI":"10.1378\/chest.107.4.1062"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/750275"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.54.3597"}],"container-title":["Respirology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fresp.13054","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/resp.13054","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T15:52:08Z","timestamp":1696175528000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/resp.13054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,25]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["10.1111\/resp.13054"],"URL":"https:\/\/doi.org\/10.1111\/resp.13054","archive":["Portico"],"relation":{},"ISSN":["1323-7799","1440-1843"],"issn-type":[{"type":"print","value":"1323-7799"},{"type":"electronic","value":"1440-1843"}],"subject":[],"published":{"date-parts":[[2017,4,25]]}}}